A new market beckons for Alzheimer’s blood tests
If drugs acting on amyloid and tau can defy the sector’s history of failure, the testing landscape will change dramatically.
Obfuscation and evasion: Astra shows how not to disclose data
The UK group’s disastrous PR strategy could erode trust in its Covid-19 vaccine even further.
The Huntington’s pipeline takes a blow
The failure of Roche and Ionis’s late-stage candidate tominersen casts doubt on Wave’s approach, too.
Merck & Co makes the accelerated approval pathway its own
Since 2010 14% of US accelerated approvals have been granted to Merck & Co’s Keytruda.
A three way battle beckons in GM1 gangliosidosis
Early data could give clues about whether gene therapies from Sio, Passage Bio or Lysogene will come out on top in this rare inherited disease.
The big Covid-19 trials still to report
New findings for IL-6 blockade in the Recovery trial finally confirm a signal. Can pending pandemic readouts for other mechanisms do the same?
Hope versus experience in glioblastoma
Development of new drugs for this hard-to-treat brain cancer is a slow and incremental process.
Galapagos “win” highlights crowded idiopathic pulmonary fibrosis pipeline
Galapagos is betting big in IPF but others, including Fibrogen and Roche, are also taking aim at the lung disease.
Ovid crashes out in Angelman syndrome
The failure of OV101 puts the spotlight on Ultragenyx and Roche.
